Neurology/CNS Preclinical Deal Benchmarks — US Only

Understanding Neurology/CNS Deal Benchmarks at Preclinical

Preclinical Neurology/CNS licensing deals in US Only territory command a median upfront payment of $18M, with values ranging from $5M at the low end to $36M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $138M to $650M, with a median of $394M. Royalty rates for neurology/cns assets at this stage typically fall between 3.6% and 7.2% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.